PULSE Regulatory Wednesday, October 7, 2026 +0.30 Positive

Pulse Biosciences achieves enrollment target in international pivotal study

Pulse Biosciences enrolled 164 patients in its pivotal NANOPULSE-AF study ahead of schedule, demonstrating strong investigator interest in its cardiac catheter system.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed